-
Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit ?
Laboratoires réunis Kutter-Lieners-Hastert, Junglinster, Luxembourg.
A group of 100 totally or subtotally myeloperoxidase (MPO)-deficient individuals was compared to a reference population of 118 probands selected at random. Data for a protective effect of the deficiency against cardiovascular damage are presented. On the other hand, a significantly higher occurrence of severe infections and chronic inflammatory processes was noted among the deficient patients. An increased incidence of cancer among the MPO-deficient individuals was not demonstrated. Copyright 2000 S. Karger AG, Basel
PMID: 11111115 [PubMed - indexed for MEDLINE]
-
Cited by 5 PubMed Central articles
-
ReviewMyeloperoxidase: a target for new drug development?
Malle E, Furtmüller PG, Sattler W, Obinger C.
Br J Pharmacol. 2007 Nov; 152(6):838-54. Epub 2007 Jun 25.
[Br J Pharmacol. 2007]
-
The human myeloperoxidase gene is regulated by LXR and PPARalpha ligands.
Reynolds WF, Kumar AP, Piedrafita FJ.
Biochem Biophys Res Commun. 2006 Oct 20; 349(2):846-54. Epub 2006 Aug 31.
[Biochem Biophys Res Commun. 2006]
-
Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease.
Zheng L, Nukuna B, Brennan ML, Sun M, Goormastic M, Settle M, Schmitt D, Fu X, Thomson L, Fox PL, et al.
J Clin Invest. 2004 Aug; 114(4):529-41.
[J Clin Invest. 2004]
- » See all...